Anesiva Logo


Investor Relations

Anesiva, Inc. (Nasdaq: ANSV) is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.

The investor pages that follow are your resource for financial information about Anesiva. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.

  Click here to download our most recent fact sheet.

Recent Releases

Apr 8, 2008
Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement

Mar 25, 2008
Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy

more »

FORWARD LOOKING STATEMENTS

This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Anesiva's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks related to the progress, timing and results of Anesiva's clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, and other risks detailed in Anesiva's filings with the Securities and Exchange Commission.